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Liver enzymesThe relationship of NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms with mild elevation of liver biomarkers
was investigated in individuals under anti-tuberculosis drug therapy. Tuberculosis outpatients (18–70 y)
with (n=59) and without (n=40) mild increase of liver enzymes (MILE) at two-month treatment were
selected. Blood samples were obtained for DNA extraction and evaluation of serum markers of liver function.
NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms were detected by DNA sequencing, PCR-RFLP, and PCR mul-
tiplex. Frequency of NAT2*5/*5 genotype was higher in MILE than in non-MILE group (p=0.04). Patients car-
rying NAT2*5/*5 genotype had increased susceptibility to MILE (OR: 9.00, 95CI: 1.46–55.48, p=0.018).
CYP2E1*5B allele (*1A/*5B plus *5B/*5B genotypes) carriers had a trend for reduced risk for MILE (OR: 0.34,
95CI: 0.11–1.03, p=0.056) that was conﬁrmed by lower levels of liver markers than CYP2E1*1A/*1A carriers
after treatment (pb0.05). Moreover, increased post-treatment ALT, AST and total bilirubin were associated
with GSTM1*1/GSTT1*1 genotypes (pb0.05). Patients taking CYP2E1 inhibitors had increased susceptibility
to MILE (OR: 7.39, 95CI: 1.93–28.29, p=0.003), which was independent of the studied polymorphisms.
These results are suggestive that NAT2, CYP2E1 and GSTM1/GSTT1 polymorphisms and concomitant use of
CYP2E1 inhibitors contribute to the susceptibility to mild alterations in liver enzymes in patients under
anti-tuberculosis drug therapy.
© 2012 Elsevier B.V. Open access under the Elsevier OA license.
 1. Introduction
Tuberculosis treatment is based on the use of isoniazid, rifampicin
and pyrazinamide, which were shown to cause adverse drug reactions
(ADRs), including hepatitis, gastrointestinal intolerance, kidney failure,
and cutaneous and hematological reactions [1], which can lead to
therapy discontinuation or more serious morbidity and mortality.
The incidence of anti-tuberculosis drug-induced hepatotoxicity
ranges from 1% to 36% [1–4]. Advanced age, gender, alcoholism, malnu-
trition, HIV co-infection, pre-existent liver disease and drug interactions
are common risk factors for hepatotoxicity [4,5]. Genetic background,
such as the isoniazid acetylator status, has also an important role on
the likelihood of developing hepatotoxicity and other ADRs [2].
N-acetyltransferase 2 (NAT2) metabolizes isoniazid into acetyl isonia-
zid, which is hydrolyzed to acetyl hydrazine [6]. Acetyl hydrazine isaulo, Faculdade de Ciencias
o Paulo, SP, Brazil. Tel.: +55 11
.
vier OA license.further oxidized into hepatotoxic intermediates by cytochrome P450
2E1 (CYP2E1). Direct hydrolysis of isoniazid also generates hydrazine, a
potent hepatotoxin. Glutathione S-transferases (GSTs) are detoxiﬁcation
enzymes that catalyze the conjugation of glutathione to several classes
of molecules including toxic intermediates of the isoniazid metabolism.
NAT2 polymorphisms have been shown to cause individual variation
in isoniazid N-acetylation having the slow acetylators more susceptibil-
ity to develop hepatotoxicity than thosewith high NAT2 activity [6–11].
Common polymorphisms in the CYP2E1 have also shown to be associat-
ed with drug-induced hepatotoxicity in tuberculosis patients [6,12].
Homozygosis of GSTT1 or GSTM1 non-functional (null) genotypes,
which cause lack of enzyme activity, was suggested to increase the
risk for hepatotoxicity to anti-tuberculosis drugs [6,13,14].
Although a relationship between gene polymorphisms and anti-
tuberculosis drug-induced hepatotoxicity has been described in
various studies, there is still limited information in our population,
which has a heterogeneous genetic background. We have investigat-
ed the contribution of NAT2, CYP2E1, GSTM1 and GSTT1 variants to the
mild increase in the liver enzymes in a sample of non-HIV outpatients
under anti-tuberculosis drug therapy.
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2.1. Patients
Tuberculosis outpatients, aged 18–70 years, were recruited at the
Clemente Ferreira Institute (Sao Paulo, SP, Brazil) and at the Center
for Health Sciences, State University of Maringa (Maringa, PR, Brazil)
from 2006 to 2008. From this sample, we selected 59 individuals with
mild increase of liver enzymes (MILE) at two-month anti-tuberculosis
drug therapy and 40 without MILE (control group). MILE was consid-
ered an increase in the serum ALT 126–250 U/L (2.5–5 times the
upper limit of normal) [4].
Active tuberculosis was diagnosed by either clinical (positive
X-ray and symptoms) and laboratory data (positive sputum smear
or culture). Individuals with HIV or viral hepatitis infection, liver dys-
function (increased baseline aminotransferases and bilirubin), alco-
holic liver disease, history of chronic liver disease, concomitant use
of hepatotoxic drugs, and pregnant women were not included in
this study. The frequency of moderate (2%) and severe (1%) hepato-
toxicity was low in the initial sample therefore these individuals
were not considered in the analysis.
Information on age, gender, self-reported ethnics, alcohol intake,
and medication in use were recorded. Each individual declared his
ethnical group during the interview and agreed to participate in the
study by signing an informed consent. The study protocol was
approved by the Ethics Committees of the School of Pharmaceutical
Sciences (University of Sao Paulo, Sao Paulo, SP, Brazil), and the
State University of Maringa.Table 1
Demographic, clinical and laboratory data of tuberculosis patients.
Variables Total (99) MILE (59) Non-MILE (40) p
Gender
Male 53.5% (53) 49.2% (29) 60.0% (24) 0.288
Female 46.5% (46) 50.8% (30) 40.0% (16)
Age
b50 years 83.8% (83) 86.4% (51) 80.0% (32) 0.5652.2. Anti-tuberculosis therapy and clinical assessment
All selected patients were treatedwith an anti-tuberculosis regimen
(daily doses of isoniazid, up to 300 mg; rifampicin, up to 600 mg;
pyrazinamide, up to 2000 mg) according to the Brazilian guidelines
on tuberculosis [15], with discontinuation of pyrazinamide at two-
month treatment. Patients underwent routine follow-up of clinical
assessments every two-weeks during the ﬁrst month and monthly
afterwards. Concomitant medications were also registered.
Serum markers of liver function (aminotransferases, alkaline
phosphatase, gamma-glutamyl transpeptidase and total bilirubin)
were measured using routine laboratory methods, before and after
2, 4 and 6 months of therapy. ≥50 years 16.2% (16) 13.6% (8) 20.0% (8)
Ethnics
White 60.6% (60) 66.1% (39) 52.5% (21) 0.223
Black 39.4% (39) 33.9% (20) 47.5% (19)
Alcohol intake (>1 g/day) 7.1% (7) 5.1% (3) 10.0% (4) 0.349
Hepatotoxicitya 11.1% (11) 18.6% (11) 0% (0) 0.003
Concomitant medication
CYP2E1 inducers 16.2% (16) 18.6% (11) 12.5% (5) 0.004
Inhibitors 20.2% (20) 28.8% (17) 7.5% (3)
Both 10.1% (10) 13.6% (8) 5.0% (2)
No med/no effectb 53.5% (53) 39.0% (23) 75.0% (30)
Liver biomarkers Basal Two-month treatment
ALT, U/L 38±5 141±17 37±4 0.011
AST, U/L 39±7 118±14 28±4 0.013
ALP, U/L 113±5 224±13 135±10 0.018
GGT, U/L 85±12 172±13 122±10 0.022
Total bilirubin, mg/dL 0.8±0.7 3.3±2.4 0.8±0.5 0.007
Number of individuals in parenthesis. Continuous variables are expressed as mean±
SEM and compared by t-test. Categorical variables were compared by chi-square and
Fisher's exact tests. MILE, mild increase in liver enzymes; ALT, alanine aminotransfer-
ase; AST, aspartate aminotransferase; ALP, alkaline phosphatase; GGT,
gamma-glutamyl transpeptidase.
a Hepatotoxicity: was considered as ALT or AST values >3 times the ULN, and/or
total bilirubin >2 mg/dL, according to the Brazilian Consensus on Tuberculosis.
b Without effect or use of concomitant medication.2.3. Polymorphism analysis
Genomic DNAwas isolated from 1 mL EDTA-anticoagulated whole
blood samples using a salting-out method previously described [16].
PCR-RFLP was used for detection of the NAT2 and CYP2E1 variants.
Primer sequences and PCR thermal cycling conditions are displayed at
the Supplementary table. NAT2*5, NAT2*6 and NAT2*7 amplicons were
digested during 4 h with EcoRII (Promega, Madison, WI, USA) at
60 °C, TaqI (Jena Biosciences GmbH, Germany) at 65 °C, and XhoII
(Fermentas International Inc., Ontario, Canada) at 37 °C. NAT2*4 allele
has a differential RFLP proﬁle for each endonuclease. CYP2E1 PCR
products were digested with AluI and RsaI (New England BioLabs,
USA), respectively, for 4 h at 37 °C. RFLP products were analyzed by
8.0% polyacrylamide gel electrophoresis stained with SYBR Gold®
(Molecular Probes, Invitrogen Detection Technologies, OR, USA).
RFLP strategies included a constitutive site to monitor endonuclease
activity.
A PCR multiplex assay was used to amplify GSTM1 and GSTT1 genes
simultaneously (Supplementary table), including the 182-bp CYP2E1
amplicon, which was used as an internal control of PCR reactions. PCR
products were analyzed by 0.8% agarose gel electrophoresis.2.4. DNA sequencing
NAT2 polymorphisms were also analyzed by DNA sequencing
using Mega BACE 1000 (Amersham Pharmacia Biotech, Upsala,
Sweden). Sequence data were assembled and edited using BioEdit
Sequence Alignment Editor, version 5.0.9 (Tom Hall, Department of
Microbiology, North Caroline State University, USA).
2.5. Statistical analysis
Categorical variables were compared by chi-square or Fisher's
exact test. Continuous variables were presented as mean±standard
error (SEM) and compared by t-test. Variables without normal distri-
bution were log transformed for analysis. Univariate logistic regres-
sion analysis was used to evaluate the risk of independent variables
for liver-related ADRs. Statistical tests were performed using
SigmaStat v. 2.0 (San Rafael, CA, USA), Minitab v. 14 (Minitab Inc.,
USA), R 2.7.1 (Vienna, Austria), and SPSS v. 15 (Chicago, IL, USA).
Statistical signiﬁcance was considered at pb0.05.
3. Results
Demographic, clinical and laboratory data of the tuberculosis out-
patients are shown in Table 1. Gender, age, ethnics and alcohol intake
were not associated with the MILE in this sample (p>0.05). On the
other hand, hepatotoxicity and use of concomitant medications,
such as CYP2E1 inhibitors, were more frequent in MILE than in
non-MILE patients (pb0.05). Liver markers in serum at two-month
anti-tuberculosis treatment were higher in MILE than in non-MILE
group (pb0.05).
Genotype distributions for NAT2, CYP2E1 and GSTM1 and GSTT1
variants were in Hardy–Weinberg equilibrium indicating the random
selection of patients from the sample population. Frequencies of NAT2
Table 2
Frequencies of NAT2, CYP2E1, GSTM1 and GSTT1 polymorphisms in tuberculosis
patients.
Variants MILE (59) Non-MILE (40) p-Value
NAT2*4/*4 10.2% (6) 22.5% (9) 0.157
NAT2*4/*5 28.8% (17) 20.0% (8)
NAT2*4/*6 11.9% (7) 17.5% (7)
NAT2*4/*7 1.7% (1) 7.5% (3)
NAT2*5/*5 20.3% (12) 5.0% (2)
NAT2*5/*6 16.9% (10) 15.0% (6)
NAT2*5/*7 1.7% (1) 7.5% (3)
NAT2*6/*6 6.8% (4) 5.0% (2)
NAT2*6/*7 1.7% (1) 0.0% (0)
CYP2E1*1A/*1A 89.8% (53) 75.0% (30) 0.199
CYP2E*1A/*5B 8.5% (5) 22.5% (9)
CYP2E*5B/*5B 1.7% (1) 2.5% (1)
GSTM1/GSTT1
M1*1/T1*1 47.4% (28) 40.0% (16) 0.690
M1*1/T1 null 10.2% (6) 7.5% (3)
M1 null/T1*1 35.6% (21) 40.0% (16)
M1 null/T1 null 6.8% (4) 12.5% (5)
Categorical variables were compared by chi-square test. MILE, mild increase in liver
enzymes.
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patients (Table 2). However, the frequency of NAT2*5/*5 genotype
was four times higher in MILE (20.3%) compared to non-MILE group
(5.0%, p=0.04). Logistic regression analysis showed that tuberculosis
patients with slow acetylation proﬁle display a trend of association
with MILE (p=0.061) (Table 3). Further analysis showed that
patients carrying the NAT2*5/*5 genotype had increased susceptibility
to MILE (OR: 9.00, 95CI: 1.46–55.48, p=0.018) compared to the
NAT2*4/*4 genotype carriers (fast acetylators) (data not shown). On
the other hand, we could not observe a relationship between slow
acetylation proﬁle and altered serum liver markers at two-month
anti-tuberculosis treatment (data not shown).
A direct relationship between CYP2E1 polymorphism and MILE
was not found in this sample (p=0.199) (Table 2); the frequency
of CYP2E1*1A/*5B genotype was slightly lower in MILE (8.5%) than
in non-MILE patients (22.5%). Logistic regression analysis indicated
that CYP2E1*5B allele (*1A/*5B plus *5B/*5B genotype) is slightly
associated with a reduced risk for MILE (OR: 034, 95CI: 0.11–1.03,Table 3
Logistic regression analysis of variables associated with MILE in tuberculosis patients.
Variables Odds ratio 95CI p
NAT2 acetylation proﬁle
Fast (*4/*4, n=15) [ref] 1.00 – –
Intermediate (*4/*5, *4/*6; *4/*7, n=43) 2.08 [0.63–6.90] 0.230
Slow (*5/*5, *5/*6, *5/*7, *6/*6 , *6*7, n=41) 3.23 [0.96–10.99] 0.061
CYP2E1 genotypes
*1A/*1A (n=83) [ref] 1.00 – –
*1A/*5B and *5B/*5B (n=16) 0.34 [0.11–1.03] 0.056
GSTM1/GSTT1 genotypes
M1*1/T1*1 (n=44) [ref.] 1.00 – –
M1*1/T1 null (n=9) 1.14 [0.25–5.20] 0.863
M1 null/T1*1 (n=37) 0.75 [0.31–1.83] 0.529
M1 null/T1 null (n=9) 0.46 [0.11–1.95] 0.290
Concomitant medication
No med/no effect (n=53)a [ref] 1.00 – –
CYP2E1 inducers (n=16) 2.82 [0.87–9.42] 0.082
Inhibitors (n=20) 7.39 [1.93–28.29] 0.003
Both (n=10) 5.22 [1.01–26.95] 0.049
95CI, 95% Conﬁdence Interval.
a Without effect or use of concomitant medication.p=0.056) (Table 3). Furthermore, analysis of liver biomarkers
showed that individuals carrying CYP2E1 *1A/*1A genotype had
three times increase in serum ALT, AST and total bilirubin at
two-month anti-tuberculosis treatment compared with CYP2E1*5B
allele carriers (Fig. 1). The interaction between CYP2E1 and NAT2 var-
iants on serum liver markers was analyzed but patients carrying the
CYP2E1*1A/*1A genotype have similar frequencies of NAT2 genotypes
than the CYP2E1*5B allele carriers (p>0.05) (data not shown).
Frequency of GSTM1/GSTT1 genotypes did not differ between the
studied groups (Table 2) (p=0.690). The presence of one or both
null genotypes was not associated with MILE by logistic regression
analysis (p>0.05) (Table 3). Analysis of the liver marker proﬁle
showed that individuals carrying the GSTM1*1/GSTT1*1 genotypes
had increased ALT and AST at two-month tuberculosis treatment
compared with null genotype carriers (pb0.05) (Fig. 2). These results
were not inﬂuenced by NAT2 or CYP2E1 genotypes (data not shown).
The use of CYP2E1 inhibitors was associated with seven times
more chance to have MILE in this sample (OR: 7.39, 95CI: 1.93–28.29,0 50 100 150 200
AST (U/L)







Fig. 1. Serum aminotransferases and total bilirubin according to CYP2E1 genotypes in
patients on anti-tuberculosis therapy. Results are expressed as mean±SEM and com-
pared by t-test (*pb0.05). ALT: alanine aminotransferase; AST: aspartate transaminase.
*5B carriers: *1A/*5B plus *5B/*5B genotypes.
















Fig. 2. Serum aminotransferases and total bilirubin according to GSTM1/GSTT1 geno-
types in patients on anti-tuberculosis therapy. Results are expressed as mean±SEM
and compared by t-test (*pb0.05). ALT: alanine aminotransferase; AST: aspartate
transaminase. Null: GSTM1 and/or GSTT1 null genotypes.
218 F.J. Forestiero et al. / Clinica Chimica Acta 415 (2013) 215–219p=0.003) comparedwith individuals without concomitantmedication
or taking medication without effect on CYP2E1 activity. Moreover indi-
viduals taking CYP2E1 inhibitors plus inducers have also increased sus-
ceptibility to MILE (OR: 5.22, 95CI: 1.01–26.95, p=0.049). Further
analysis showed that these relationships were not inﬂuenced by NAT2,
CYP2E1 or GSTM1/GSTT1 polymorphisms (p>0.05, data not shown).
4. Discussion
Exposition to anti-tuberculosis drugs over a long period of time
can result in severe hepatotoxicity in susceptible patients. Gender,
age, ethnics background and alcohol intake have been proposed to
play important roles in the pathogenesis of anti-tuberculosis drug
induced hepatotoxicity (ADIH) [5,17], however we could not ﬁnd a sig-
niﬁcant relationship of this variables with MILE. The use of CYP2E1
inhibitors was an important variable associated with MILE in this sam-
ple, suggesting their potential interaction with anti-tuberculosis drugs
to develop liver injury. Inhibition of CYP2E1 could increase plasma con-
centration of other hepatotoxic drugs metabolized by CYP2E1, and
therefore increase the susceptibility to MILE.Analysis of polymorphisms showed that frequencies of NAT2 func-
tional and non-functional (slow acetylators) genotypes were similar
to the overall frequencies previously described in Brazil [10,18] and in
other populations [19–24]. Distribution of CYP2E1, GSTM1 and GSTT1
genotypes did not also differ from that reported in other studies
[19,22,25–30].
Gene candidate association analysis showed a signiﬁcant relationship
between NAT2*5/*5 genotype and MILE. Reduced hepato-protective
effect in slow acetylators, including NAT2*5/*5 carriers, has been shown
in patients under anti-tuberculosis therapy from other populations
[21–23,31,32]. Recently slow acetylation status was also found to be an
increased risk factor for anti-tuberculosis drug-induced hepatotoxicity
in another sample of Brazilian population (OR: 3.59, 95%CI: 2.53–4.68,
p=0.02) [30].
NAT2*5/*5 and other non-functional genotypes lack the normal
acetylation rate of isoniazid and its metabolites causing accumulation
of hydrazine, a potent hepatotoxic compound [19,29,33–35]. The
results from this study are suggestive that the susceptibility of NAT2
slow acetylators to anti-tuberculosis drug-induced liver injury shown
in a number of studies [21–23,30–32,36] may depend on other risk fac-
tors. However, we could not detect any interaction of NAT2 variants
with CYP2E1 and GSTM1/GSTT1 polymorphisms, concomitant medica-
tions and other variables, which could be related to MILE, suggesting a
major role of the NAT2*5*5 genotype.
In this sample, increased serum ALT, AST and bilirubin was found
in CYP2E1*1A/*1A (wild type) genotype carriers suggesting that these
individuals are more susceptible to liver injury under anti-tuberculosis
therapy. Likewise, increased ALT activity was also found in pulmonary
tuberculosis patients carrying CYP2E1 c1/c1 genotype [37]. Results
from a meta-analysis study have shown that CYP2E1*1A/*1A genotype
increases the risk for ADIH [38]. CYP2E1 c1/c1 RsaI genotype (wild
type) was also suggested to be a potential risk factor for ADIH in the
Chinese population [28]. Moreover, Lee and colleagues [22] have
reported that CYP2E1 c1/c1 genotype carriers are prone to developing
more severe hepatotoxicity (increased AST levels) than other c1/c2
and c2/c2 genotypes.
Even though CYP2E1 promoter variant has not been associated
with basal enzymatic levels, CYP2E1 activity is less inhibited by isoni-
azid in CYP2E1*1A/*1A genotype carriers than those individuals carry-
ing CYP2E1*1A/*5 or CYP2E1*5/*5 genotypes [39]. This effect may
explain the relationship between CYP2E1*1A/*1A genotype and
increased serum biomarkers of liver injury under anti-tuberculosis
drug therapy. Therefore, CYP2E1*1A/*1A genotype carriers are prone
to produce more hepatotoxins and increased risk for hepatotoxicity
under anti-tuberculosis therapy [6].
A recent study has shown that the combination of the CYP2E1 c1/c1
genotype with a slow acetylator NAT2 genotype increased the risk of
ADIH in Chinese tuberculosis patients [40]. In our sample, NAT2 slow
acetylator proﬁle was not associated with CYP2E1 variants suggesting
their independent contribution to MILE susceptibility in patients under
anti-tuberculosis treatment. However, further studies are necessary to
evaluate NAT2 and CYP2E1 interactions in larger sample populations.
It is likely that co-administration with CYP2E1 substrates or
inducers, such as acetaminophen and ethanol, may exert additional
liver injury effect on individuals carrying CYP2E1*1A/*1A genotype
treated with anti-tuberculosis drugs. However we could not demon-
strate a relationship between alcohol consumption and/or concomi-
tant use of CYP2E1 inducers or inhibitors and MILE in this sample.
GSTM1 and GSTT1 have an important role in the detoxiﬁcation of
hydrazine and other toxic reactive compounds. Even though the
GSTM1 and GSTT1 null genotypes have been associated with increased
ADIH [6,13,14], a modest effect of GSTM1 null genotype on genetic
susceptibility to ADIH was reported by a meta-analysis, but no signif-
icant evidence for GSTT1 null [40]. Moreover, the relationship of these
null genotypes with ADIH was not conﬁrmed in recent case–control
association studies [27–30].
219F.J. Forestiero et al. / Clinica Chimica Acta 415 (2013) 215–219The relationship between GSTM1*1/GSTT1*1 genotype and increased
serum ALT and AST during anti-tuberculosis therapy found in this study
was not inﬂuenced by interactionwithNAT2 and CYP2E1 polymorphisms.
Effects of GSTM1 and GSTT1 null genotypes on hydrazine serum levels
were investigated by Fukino and colleagues [19]. Hydrazine was prone
to be accumulated in NAT2 intermediate acetylators carrying the GSTM1
null genotype. Conversely, GSTT1 null genotype carriers also have
increased hydrazine in intermediate acetylator group. It is likely that the
GSTM1 and GSTT1 null variants have a minor contribution to the liver
injury caused by exposure to anti-tuberculosis drugs in comparison
with NAT2 non-functional alleles or even CYP2E1 common genotypes.
In conclusion, besides theNAT2, CYP2E1 and GSTM1/GSTT1 polymor-
phisms, the use of CYP2E1 inhibitors contributes to the susceptibility to
mild alterations in liver enzymes in patients under anti-tuberculosis
drug therapy.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.cca.2012.10.030.
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